It was a volatile week in the US, with tech stocks selling off on Monday in response to claims that a Chinese company had developed AI algorithms that needed far less computing power. The rest of the week saw partial recovery. Although it meant that the FTSE100 had a rare week in the sun, outperforming the S&P500.
Here’s what we can look forward to next week:
Economic Calendar
Monday 3rd |
||
01:45 09:00 09:30 15:00 |
China Euro Area UK United States |
Manufacturing PMI |
10:00 |
Euro Area |
Inflation |
Tuesday 4th |
||
15:00 |
United States |
Job Openings |
Wednesday 5th |
||
00:30 09:00 09:30 15:00 |
Japan Euro Area UK United States |
Services PMI |
Thursday 6th |
||
12:00 |
UK |
BOE Interest Rate Decision MPC Meeting Minutes |
Friday 7th |
||
07:00 |
UK |
Halifax House Price Index |
13:30 |
United States |
Unemployment Rate Non-Farm Payrolls |
15:00 |
United States |
Consumer Sentiment |
The key news next week will be UK interest rates. Since the base Rate peaked at 5.25% in August 2023, there have been two 25bps cuts in August and November 2024:
The Bank of England is forecast to make a further 25bps next week.
Companies Reporting
UK Trading Updates |
UK Financial Results |
US Financial Results |
|
Monday 4 Feb |
Entain Vodafone |
Palantir |
|
Tuesday 4 Feb |
DCC Future (AGM) SSE |
Crest Nicholson (Finals) Diageo (Interims) NWF (Interims) |
Alphabet Merck PepsiCo AMD Pfizer Paypal Mondelez |
Wednesday 5 Feb |
Grainger (AGM) | GSK (Q4 Results) Made Tech (Interims) Pressure Technologies (Finals) |
Disney Qualcomm Boston Scientific Uber Ford |
Thursday 6 Feb |
Compass Syncoma |
AstraZeneca (Finals) |
Amazon Phillip Morris S&P Global Honeywell KKR ConocoPhillips Motorola |
Friday 7 Feb |
Victrex (AGM) | Ashmore (Interims) |
Big Pharma
Big Pharma will be in focus next week as we have AstraZeneca (LON:AZN) Finals and GSK (LON:GSK) Q4 Results being reported. Both companies have underperformed the FTSE100 over the last year:
With GSK underperforming by almost 20%. Broker downgrades, particularly to FY25, seem to be the…
